Skip to main content

Diarrhea Infectious

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Diagnostic test: Accessible Diarrhea Etiology Prediction ToolN/A1 trial
Active Trials
NCT07538531Not Yet Recruiting30Est. Jun 2026
Pharmaron
PharmaronRI - Coventry
1 program
VENBETA6890PHASE_11 trial
Active Trials
NCT06896136Completed36Est. May 2025

Trial Timeline

Clinical trial activity over time

2025
2026
PharmaronVENBETA6890
Human BioSciencesDiagnostic test: Accessible Diarrhea Etiology Prediction Tool

Clinical Trials (2)

Total enrollment: 66 patients across 2 trials

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

Start: Feb 2025Est. completion: May 202536 patients
Phase 1Completed
NCT07538531Human BioSciencesDiagnostic test: Accessible Diarrhea Etiology Prediction Tool

The Utility and Feasibility of Accessible Diarrhea Etiology Prediction Tool (ADEPT) in an Informal Healthcare Setting

Start: Apr 2026Est. completion: Jun 202630 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.